Hajime Kato
Associate Research Scientist in PathologyCards
About
Research
Publications
2025
The prevalence of ENPP1 deficiency in humans with OPLL and the preclinical efficacy of ENPP1 enzyme therapy in OPLL mice
Srivastava S, Kato H, von Kroge S, Weise K, Stabach P, Lopez S, O’Brien K, Lester E, Kim H, Ishaq T, Dammen-Brower K, Schinke T, Kimura S, Miyahara J, Doi T, Oshima Y, Yarema K, Carpenter T, Sabbagh Y, Tommasini S, Ito N, Oheim R, Braddock D. The prevalence of ENPP1 deficiency in humans with OPLL and the preclinical efficacy of ENPP1 enzyme therapy in OPLL mice. Journal Of Bone And Mineral Research 2025, zjaf168. PMID: 41251406, DOI: 10.1093/jbmr/zjaf168.Peer-Reviewed Original ResearchDiffuse idiopathic skeletal hyperostosisENPP1 deficiencyPreclinical efficacyOPLL patientsPlasma levelsBone fragilitySpinal fracture riskMonoallelic pathogenic variantsCortical bone microarchitectureEnzyme replacement therapyPosterior longitudinal ligamentAlkaline phosphatase levelsIdiopathic skeletal hyperostosisLong bonesPathogenesis of OPLLPlasma PPiSpinal fracturesReplacement therapySurgical correctionFracture riskProspective studyPhosphate wastingLongitudinal ligamentBone microarchitecturePathogenic variantsPHEX Protein in the Parathyroid Gland Contributes to Phosphate Sensing
Irie K, Kato H, Adachi N, Kimura S, Hoshino Y, Hidaka N, Tanaka S, Nangaku M, Saito T, Makita N, Ito N. PHEX Protein in the Parathyroid Gland Contributes to Phosphate Sensing. The Journal Of Clinical Endocrinology & Metabolism 2025, dgaf357. PMID: 40512822, DOI: 10.1210/clinem/dgaf357.Peer-Reviewed Original ResearchTumor-induced osteomalaciaX-linked hypophosphatemiaSerum Pi levelsIntact PTHParathyroid hormoneParathyroid glandsPi loadingFibroblast growth factorTumor-induced osteomalacia patientsPHEX proteinX-linked hypophosphatemia patientsOral phosphate administrationSerum cCa levelIntact parathyroid hormoneParathyroid hormone secretionLoss-of-function variantsPi levelsTertiary hyperparathyroidismPHEX geneSerum PiPhosphate administrationPatientsGrowth factorPHEXSerumAcquired Osteomalacia Associated with Autoantibodies against PHEX
Hoshino Y, Okamoto K, Ogawa T, Kato H, Irie K, Watanabe S, Kimura S, Hidaka N, Kinoshita Y, Kobayashi H, Hagiwara D, Kogawa M, Takayanagi H, Tanaka S, Nangaku M, Makita N, Burbelo P, Saito T, Ito N. Acquired Osteomalacia Associated with Autoantibodies against PHEX. The New England Journal Of Medicine 2025, 392: 513-515. PMID: 39879599, PMCID: PMC11781776, DOI: 10.1056/nejmc2405746.Peer-Reviewed Original ResearchExcess fibroblast growth factor 23 in alcoholic osteomalacia is derived from the bone
Hidaka N, Oyama Y, Koga M, Kondo N, Yasunaga Y, Shimakura T, Yamamoto N, Takahashi H, Iwafuchi Y, Watanabe S, Kimura S, Hoshino Y, Kato H, Kinoshita Y, Kobayashi H, Tanaka T, Ushiku T, Nangaku M, Tanaka S, Makita N, Saito T, Ito N. Excess fibroblast growth factor 23 in alcoholic osteomalacia is derived from the bone. JBMR Plus 2025, 9: ziaf010. PMID: 39963340, PMCID: PMC11831984, DOI: 10.1093/jbmrpl/ziaf010.Peer-Reviewed Original ResearchFGF23-related hypophosphatemic osteomalaciaPhosphor-integrated dotsHypophosphatemic osteomalaciaFGF23-related hypophosphatemiaSecretion of FGF23Differential diagnosisFGF23 expressionExcessive fibroblast growth factor 23Cessation of alcohol consumptionFGF23 expression levelsTumor-induced osteomalaciaFibroblast growth factor 23Rare conditionSensitive immunohistochemistryAlcoholic patientsPhosphaturic hormoneFibroblast growth factorOsteomalaciaExcess FGF23Conventional immunohistochemistryImmunohistochemistryFGF23Immunohistochemical approachReference levelGrowth factor
2024
Effect of Mutation Type on Ectopic Ossification Among Adult Patients With X-Linked Hypophosphatemia
Kato H, Ishihara Y, Ohata Y, Irie K, Watanabe S, Kimura S, Hoshino Y, Hidaka N, Kinoshita Y, Taniguchi Y, Kobayashi H, Braddock D, Kubota T, Ozono K, Nangaku M, Makita N, Ito N. Effect of Mutation Type on Ectopic Ossification Among Adult Patients With X-Linked Hypophosphatemia. Journal Of The Endocrine Society 2024, 8: bvae184. PMID: 39498416, PMCID: PMC11532897, DOI: 10.1210/jendso/bvae184.Peer-Reviewed Original ResearchX-linked hypophosphatemiaNonsense-mediated decayEctopic ossificationPathogenic variantsSpinal computed tomography scansMutation typeInhibitor of tissue calcificationComputed tomography scanSpinal ligament ossificationGenotype-phenotype correlationKellgren-Lawrence classificationNon-consanguineous familyPHEX mutationsPHEX variantAdult patientsTomography scanLigament ossificationFibroblast growth factorYellow ligamentOS indexKellgren-LawrenceStudy populationTissue calcificationPatientsProtein functionCorrection of Paradoxical Mineralization in Murine CKD-MBD by ENPP1 Enzyme Biologics
Kato H, Kim H, Ishaq T, Sims D, Srivastava S, Stabach P, Carpenter T, O'Neill W, Braddock D. Correction of Paradoxical Mineralization in Murine CKD-MBD by ENPP1 Enzyme Biologics. Journal Of The American Society Of Nephrology 2024, 35: 10.1681/asn.2024sre0cym1. DOI: 10.1681/asn.2024sre0cym1.Peer-Reviewed Original ResearchLatent metabolic bone disease, skeletal dysplasia and other conditions related to low bone formation among 38 patients with subtrochanteric femoral fractures: a retrospective observational study
Kimura S, Sunouchi T, Watanabe S, Hoshino Y, Hidaka N, Kato H, Takeda S, Nangaku M, Makita N, Azuma K, Kojima T, Matsubara T, Saito T, Ito N. Latent metabolic bone disease, skeletal dysplasia and other conditions related to low bone formation among 38 patients with subtrochanteric femoral fractures: a retrospective observational study. Osteoporosis International 2024, 35: 1633-1643. PMID: 38951164, PMCID: PMC11364693, DOI: 10.1007/s00198-024-07168-4.Peer-Reviewed Original ResearchConceptsAtypical femoral fracturesLow bone formationSubtrochanteric femoral fracturesMetabolic bone diseaseLoss-of-function variantsBone diseaseFemoral fracturesAntiresorptive agentsBone formationSerum alkaline phosphatase levelsSkeletal dysplasiaOral glucocorticoid useUniversity of Tokyo HospitalDepartment of Orthopedic SurgeryRetrospective observational studyAlkaline phosphatase levelsLong-term useHypophosphatemic osteomalaciaClinical fracturesGlucocorticoid useRecurrent fracturesJapanese patientsSpinal surgeryMethodsClinical informationOsteoporotic patients#1950 Burosumab activity on osteomalacia—a TIO case report
Foligno N, Kato H, Hoshino Y, Kimura S, Sunouchi T, Hidaka N, Watanabe S, Vezzoli G, Ito N. #1950 Burosumab activity on osteomalacia—a TIO case report. Nephrology Dialysis Transplantation 2024, 39: gfae069-0454-1950. DOI: 10.1093/ndt/gfae069.454.Peer-Reviewed Original ResearchTumor-induced osteomalaciaActive vitamin DVitamin D levelsBone painBone scintigraphyVitamin DD levelsTreatment of X-linked hypophosphatemic ricketsImprovement of osteomalaciaRare paraneoplastic disorderX-linked hypophosphatemic ricketsTreatment of choiceNon-surgical patientsReabsorption of phosphateRight proximal tibiaProximal tubular cellsPathological accumulationParaneoplastic disordersSurgical resectionPathological fracturesSerum phosphateM patientsCase reportConventional therapyHypophosphatemic ricketsCardiovascular Outcomes of KCNJ5 Mutated Aldosterone-Producing Adenoma: A Systematic Review
Kato H, Kitamoto T, Kimura S, Sunouchi T, Hoshino Y, Hidaka N, Tsurutani Y, Ito N, Makita N, Nishikawa T, Nangaku M, Inoue K. Cardiovascular Outcomes of KCNJ5 Mutated Aldosterone-Producing Adenoma: A Systematic Review. Endocrine Practice 2024, 30: 670-678. PMID: 38657793, DOI: 10.1016/j.eprac.2024.04.007.Peer-Reviewed Original ResearchConceptsAldosterone-producing adenomaRisk of biasCure of hypertensionKCNJ5 mutationsNon-randomized studiesSystematic reviewCardiovascular outcomesClinical featuresCardiac functionMetabolic outcomesPotential burdenSerious risk of biasSystematic review of observational studiesReview of observational studiesObservational studyNon-randomized Studies of InterventionsModerate riskModerate risk of biasImpaired cardiac functionStudies of interventionsUnfavorable cardiovascular outcomesQuality of evidenceKCNJ5 mutational statusPrimary aldosteronismMutation statusAcquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia
Ito N, Hidaka N, Kato H. Acquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia. Endocrinology And Metabolism 2024, 39: 255-261. PMID: 38467164, PMCID: PMC11066443, DOI: 10.3803/enm.2023.1908.Peer-Reviewed Original ResearchConceptsTumor-induced osteomalaciaDifferential diagnosisFibrous dysplasia/McCune-Albright syndromePositron Emission Tomography/Computed TomographyAutosomal dominant hypophosphatemic ricketsEmission Tomography/Computed TomographyCessation of drugFibroblast growth factor 23FGF23-producing tumorsSerum phosphate levelsAdequate differential diagnosisIdentification of FGF23Tomography/Computed TomographyTherapeutic optionsRegulation of serum phosphate levelVenous samplingHypophosphatemic ricketsInvasive proceduresHypophosphatemic rickets/osteomalaciaHumoral factorsSyndromeMedical costsPhosphate levelsOsteomalaciaPatients
Academic Achievements & Community Involvement
News
Get In Touch
Contacts
Email